arrow
Á

Álvaro González-Cantero

Hospital Universitario Ramón y Cajal
H指数:17
被引数:934

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Distinct Gut Microbiota Signatures are Associated With Progression of Atherosclerosis in Patients With Psoriasis: Results From the EDSAP Study

银屑病患者中独特的肠道微生物群特征与动脉粥样硬化进展相关:EDSAP研究的结果

2026-10-140
PRE
Safety and effectivity of dupilumab in transplant recipients with severe atopic dermatitis: A multicenter case series

Dupilumab在严重特应性皮炎移植受者中的安全性与有效性:一项多中心病例系列研究

2026-09-230
PRE
Blood proteomics links systemic inflammation with early atherosclerosis in moderate-to-severe atopic dermatitis

血液蛋白质组学将系统性炎症与中重度特应性皮炎的早期动脉粥样硬化联系起来

2026-09-090
PRE
Multidisciplinary Management in Psoriasis: A Structured Approach for Early Comorbidity Detection and Referral

银屑病中的多学科管理:早期共病检测和转诊的结构化方法

2026-04-180
OAAI
Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping study

为以患者为中心的国际银屑病结局奠定基础: 范围研究

2026-02-050
PREAI
Prevalence, multiterritorial vascular distribution, and burden of subclinical atherosclerosis in psoriasis: The EDSAP study

银屑病中临床前动脉粥样硬化的患病率、多地域血管分布及其负担:EDSAP研究

2026-01-012
OAAI
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

每日一次口服icotrokinra与安慰剂及每日一次口服deucravacitinib对比,用于中重度斑块状银屑病患者的两项Ⅲ期、随机、安慰剂对照和活性对照药对照试验(ICONIC-ADVANCE 1 & 2)

2025-09-180
PRE
Establishing Consensus on Defining Failure of Topical Therapy in Psoriasis: Recommendations from the International Psoriasis Council

建立银屑病外用治疗效果不佳的定义共识:国际银屑病委员会的建议

2025-09-110
PREAI
Tildrakizumab in Psoriatic Patients With Current or Past Malignancy: A Real-Life Cohort and Literature Review

Tildrakizumab在当前或既往有恶性肿瘤的银屑病患者中的应用:一项真实世界队列研究和文献综述

2025-09-010
PRE
International Psoriasis Council psoriasis disease severity reclassification: Update on validity, acceptance, and implementation

国际银屑病协会银屑病疾病严重程度重新分类:有效性、接受度和实施情况的更新

2025-06-060
OAAI
Residual Inflammation in Patients with Psoriasis Treated with Biologic Therapy: Findings from 3 Prospective Observational Cohorts

生物制剂治疗银屑病患者的残余炎症:来自3个前瞻性观察队列的研究发现

2025-05-200
PRE
Improving the quality of life of patients with inflammatory skin diseases: a multicenter evaluation of a ceramide-containing regimen in patients with atopic dermatitis, psoriasis and xerosis

改善炎症性皮肤病患者生活质量:一项多中心评估含神经酰胺方案在特应性皮炎、银屑病和干燥症患者的应用

2025-04-080
OA
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study
2025-02-011
OAAI
Monocyte-to-High-Density Lipoprotein Ratio Is Associated with Systemic Inflammation, Insulin Resistance, and Coronary Subclinical Atherosclerosis in Psoriasis: Results from 2 Observational Cohorts
2024-09-013
PRE
Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain
2024-07-101
OA
Association of the Complement System with Subclinical Atherosclerosis in Psoriasis: Findings from an Observational Cohort Study
2024-05-013
PRE